Cargando…

IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Lenvatinib oral chemotherapy is approved as a first-line treatment of patients with unresectable HCC. The efficacy and therapeutic duration of lenvatinib are limited by drug resistance, and the mechanism is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Yarong, Xu, Jun, Du, Qiang, Yan, Yihe, Geller, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988337/ https://www.ncbi.nlm.nih.gov/pubmed/33735820 http://dx.doi.org/10.1016/j.tranon.2021.101059

Ejemplares similares

Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)
por: Yan, Yihe, et al.
Publicado: (2021)

SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway: SREBP2 Inhibitor sensitizes HCC to lenvatinib
por: Fan, Minghao, et al.
Publicado: (2023)

Interferon Regulatory Factor-1 (IRF1) activates autophagy to promote liver ischemia/reperfusion injury by inhibiting β-catenin in mice
por: Yan, Bing, et al.
Publicado: (2020)

Inhibition of Checkpoint Kinase 1 (CHK1) Upregulates Interferon Regulatory Factor 1 (IRF1) to Promote Apoptosis and Activate Anti-Tumor Immunity via MICA in Hepatocellular Carcinoma (HCC)
por: Li, Xicai, et al.
Publicado: (2023)

Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)
por: Huang, Jingquan, et al.
Publicado: (2023)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
por: Hou, Wei, et al.
Publicado: (2022)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
por: Fu, Zhigang, et al.
Publicado: (2021)

STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib
por: Zheng, Yahui, et al.
Publicado: (2021)

UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370
por: Yu, Yan, et al.
Publicado: (2020)

C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Roles of lncRNAs Mediating Wnt/β-Catenin Signaling in HCC
por: Xu, Yating, et al.
Publicado: (2022)

Division of labor between IRF1 and IRF2 in regulating different stages of transcriptional activation in cellular antiviral activities
por: Ren, Gang, et al.
Publicado: (2015)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Zhu, Jie, et al.
Publicado: (2021)

The TTYH3/MK5 Positive Feedback Loop regulates Tumor Progression via GSK3-β/β-catenin signaling in HCC
por: Wang, Yixiu, et al.
Publicado: (2022)

TRIM14 expression is regulated by IRF‐1 and IRF‐2
por: Cui, Jingang, et al.
Publicado: (2019)

RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo
por: Wang, Wei, et al.
Publicado: (2014)

IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin
por: Tian, Miao, et al.
Publicado: (2020)

Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance
por: Scheller, Marina, et al.
Publicado: (2013)

Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011)

Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma
por: QU, BO, et al.
Publicado: (2014)

Cooperation Between the NRF2 Pathway and Oncogenic β‐catenin During HCC Tumorigenesis
por: Savall, Mathilde, et al.
Publicado: (2021)

MicroRNA-23a downregulates the expression of interferon regulatory factor-1 in hepatocellular carcinoma cells
por: Yan, Yihe, et al.
Publicado: (2016)

Regulating IRFs in IFN Driven Disease
por: Jefferies, Caroline A.
Publicado: (2019)

The Epigenetic Regulation of HCC Metastasis
por: Han, Tae-Su, et al.
Publicado: (2018)

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports
por: Tian, Yuan, et al.
Publicado: (2023)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

DNA-binding landscape of IRF3, IRF5 and IRF7 dimers: implications for dimer-specific gene regulation
por: Andrilenas, Kellen K, et al.
Publicado: (2018)

Synergistic antitumor efficacy of aspirin plus lenvatinib in hepatocellular carcinoma via regulating of diverse signaling pathways
por: Yan, Xijing, et al.
Publicado: (2023)

Author Correction: IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin
por: Tian, Miao, et al.
Publicado: (2023)

CAV1 Promotes HCC Cell Progression and Metastasis through Wnt/β-Catenin Pathway
por: Yu, Hongxiu, et al.
Publicado: (2014)

High NDRG3 expression facilitates HCC metastasis by promoting nuclear translocation of β-catenin
por: Shi, JiKui, et al.
Publicado: (2019)

Promotion of growth factor signaling as a critical function of β-catenin during HCC progression
por: Kim, Eunsun, et al.
Publicado: (2019)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma
por: Deng, Ling, et al.
Publicado: (2019)

Near-infrared fluorescence imaging of hepatocellular carcinoma cells regulated by β-catenin signaling pathway
por: Song, Jian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bsu2ki4c8q9m0i68mbujrbo7sj